SCHEMBL20106662

SCHEMBL20106662

CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@H]5[C@](C(=O)O)(CC[C@@H](C)[C@@]5(C)O)CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.75
SENP1 Q9P0U3 2/20 0.75
POLB P06746 1/20 0.75
RECQL P46063 1/20 0.75
USP2 O75604 2/20 0.72
ACHE P22303 1/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
HSD11B1 P28845 2/20 0.61
PTPN2 P17706 1/20 0.61
CETP P11597 3/20 0.60
SLCO1B3 Q9NPD5 1/20 0.60
SLCO1B1 Q9Y6L6 1/20 0.60
LMNA P02545 1/20 0.60
TP53 P04637 1/20 0.60
CYP3A4 P08684 1/20 0.60
GYS2 P54840 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12181559 1.00 PTPN1 (0.75) PTPN1SENP1POLBRECQLUSP2
SCHEMBL15163877 0.94 POLB (0.68) PTPN1SENP1POLBRECQLUSP2
SCHEMBL31658620 0.87 PTPN1 (0.69) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL1049001 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL7357947 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL12181563 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL829116 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL20998163 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Pomolic Acid SCHEMBL20971332 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2
Epipomolic Acid SCHEMBL7035933 0.86 PTPN1 (1.00) PTPN1SENP1POLBRECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118657-A1 METHODS FOR INHIBITING MUSCLE ATROPHY UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118657-A1 METHODS FOR INHIBITING MUSCLE ATROPHY TNNC1, PYGM, GYS1 PTPN1 4668/4885SENP1 264/4885POLB 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.